Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Calificación de consenso1
Buy
Precio objetivo más alto1
$454.00
Precio objetivo más bajo1
$311.00
Precio objetivo consensuado1
$384.32
BeOne Medicines Ltd tiene un precio objetivo de consenso de $384.32 basado en las calificaciones de 19 analistas. El máximo es $454, emitido por TD Cowen el agosto 6, 2026. El mínimo es $311, emitido por RBC Capital el mayo 8, 2025. Las 3 calificaciones de analistas más recientes fueron publicadas por TD Cowen, RBC Capital y Truist Securities el agosto 6, 2026, respectivamente. Con un precio objetivo promedio de $440.67 entre TD Cowen, RBC Capital y Truist Securities, hay una 17.68% upside implícita para BeOne Medicines Ltd según estas calificaciones más recientes de analistas.
1calculado a partir de las calificaciones de los analistas
El último precio objetivo de BeOne Medicines (NASDAQ:ONC) fue comunicado por TD Cowen el agosto 6, 2026. La firma de analistas fijó un precio objetivo para $454.00 que espera ONC a rise dentro de 12 meses (un posible 21.24% upside). 34 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para BeOne Medicines (NASDAQ:ONC) fue proporcionada por TD Cowen, y BeOne Medicines mantuvo su buy calificación.
La última revisión al alza de BeOne Medicines Ltd se produjo en julio 13, 2026, cuando Jefferies elevó su precio objetivo a $380. Jefferies anteriormente tenía a hold para BeOne Medicines Ltd.
La última revisión a la baja de BeOne Medicines Ltd se produjo en marzo 16, 2026, cuando Jefferies cambió su precio objetivo de $420 a $290 para BeOne Medicines Ltd.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de BeOne Medicines, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de BeOne Medicines se registró el agosto 6, 2026, por lo que la próxima calificación estará disponible en torno al agosto 6, 2027.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de BeOne Medicines (ONC) fue un mantuvo con un precio objetivo de $424.00 a $454.00. El precio actual al que cotiza BeOne Medicines (ONC) es de $374.47, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.
Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas
Datos de mercado proporcionados por APIs de Benzinga
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Buy Now | Get Alert | ||||||
|---|---|---|---|---|---|---|---|
| 08/06/2026 | Buy Now | 21.24% | TD Cowen | $424 → $454 | Maintains | Buy | Get Alert |
| 08/06/2026 | Buy Now | 20.17% | RBC Capital | $451 → $450 | Maintains | Outperform | Get Alert |
| 08/06/2026 | Buy Now | 11.62% | Truist Securities | $416 → $418 | Maintains | Buy | Get Alert |
| 08/06/2026 | Buy Now | 14.83% | Guggenheim | $420 → $430 | Maintains | Buy | Get Alert |
| 08/06/2026 | Buy Now | 8.69% | Barclays | $403 → $407 | Maintains | Overweight | Get Alert |
| 08/06/2026 | Buy Now | 8.15% | Citizens | $396 → $405 | Maintains | Market Outperform | Get Alert |
| 07/23/2026 | Buy Now | 13.49% | JP Morgan | $415 → $425 | Maintains | Overweight | Get Alert |
| 07/14/2026 | Buy Now | 7.62% | Barclays | $409 → $403 | Maintains | Overweight | Get Alert |
| 07/13/2026 | Buy Now | 1.48% | Jefferies | $333 → $380 | Upgrade | Hold → Buy | Get Alert |
| 07/07/2026 | Buy Now | 20.44% | RBC Capital | $436 → $451 | Maintains | Outperform | Get Alert |
| 07/07/2026 | Buy Now | 11.09% | Truist Securities | $413 → $416 | Maintains | Buy | Get Alert |
| 07/01/2026 | Buy Now | 5.75% | Citizens | $396 → $396 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/02/2026 | Buy Now | 16.43% | RBC Capital | $425 → $436 | Maintains | Outperform | Get Alert |
| 05/15/2026 | Buy Now | -1.99% | Leerink Partners | $364 → $367 | Maintains | Outperform | Get Alert |
| 05/07/2026 | Buy Now | 13.49% | RBC Capital | $423 → $425 | Maintains | Outperform | Get Alert |
| 05/07/2026 | Buy Now | 12.16% | Guggenheim | $410 → $420 | Maintains | Buy | Get Alert |
| 05/07/2026 | Buy Now | 9.22% | Barclays | $405 → $409 | Maintains | Overweight | Get Alert |
| 05/07/2026 | Buy Now | 10.29% | Truist Securities | $411 → $413 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2026 | Buy Now | 6.82% | Wells Fargo | → $400 | Initiates | → Overweight | Get Alert |
| 03/27/2026 | Buy Now | -9.21% | Wolfe Research | → $340 | Initiates | → Outperform | Get Alert |
| 03/16/2026 | Buy Now | -22.56% | Jefferies | $420 → $290 | Downgrade | Buy → Hold | Get Alert |
| 02/27/2026 | Buy Now | 13.49% | RBC Capital | $417 → $425 | Maintains | Outperform | Get Alert |
| 02/27/2026 | Buy Now | 10.02% | Truist Securities | $400 → $412 | Maintains | Buy | Get Alert |
| 02/27/2026 | Buy Now | 9.49% | Guggenheim | $400 → $410 | Maintains | Buy | Get Alert |
| 02/27/2026 | Buy Now | 8.15% | Barclays | $394 → $405 | Maintains | Overweight | Get Alert |
| 02/04/2026 | Buy Now | 5.22% | Barclays | $385 → $394 | Maintains | Overweight | Get Alert |
| 11/24/2025 | Buy Now | 6.82% | Truist Securities | → $400 | Initiates | → Buy | Get Alert |
| 11/18/2025 | Buy Now | 8.95% | RBC Capital | $395 → $408 | Maintains | Outperform | Get Alert |
| 11/10/2025 | Buy Now | 8.15% | Citigroup | $399 → $405 | Maintains | Buy | Get Alert |
| 11/07/2025 | Buy Now | 5.48% | RBC Capital | $374 → $395 | Maintains | Outperform | Get Alert |
| 11/07/2025 | Buy Now | 5.75% | Citizens | $348 → $396 | Maintains | Market Outperform | Get Alert |
| 10/20/2025 | Buy Now | 2.28% | Morgan Stanley | $350 → $383 | Maintains | Overweight | Get Alert |
| 10/08/2025 | Buy Now | 2.81% | JP Morgan | $345 → $385 | Maintains | Overweight | Get Alert |
| 09/18/2025 | Buy Now | 2.81% | Barclays | → $385 | Initiates | → Overweight | Get Alert |
| 08/07/2025 | Buy Now | -2.8% | RBC Capital | $349 → $364 | Maintains | Outperform | Get Alert |
| 08/07/2025 | Buy Now | -2.53% | Guggenheim | $350 → $365 | Maintains | Buy | Get Alert |
| 07/17/2025 | Buy Now | -7.87% | JP Morgan | $321 → $345 | Maintains | Overweight | Get Alert |
| 07/16/2025 | Buy Now | -6.8% | RBC Capital | $311 → $349 | Maintains | Outperform | Get Alert |
| 06/27/2025 | Buy Now | -11.88% | Morgan Stanley | $313 → $330 | Maintains | Overweight | Get Alert |
| 06/27/2025 | Buy Now | -14.28% | JP Morgan | $317 → $321 | Maintains | Overweight | Get Alert |
| 06/27/2025 | Buy Now | -16.95% | RBC Capital | $311 → $311 | Reiterates | Outperform → Outperform | Get Alert |
| 05/08/2025 | Buy Now | -16.95% | RBC Capital | $312 → $311 | Maintains | Outperform | Get Alert |
| 05/08/2025 | Buy Now | -6.53% | Guggenheim | $348 → $350 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | -16.68% | RBC Capital | $312 → $312 | Reiterates | Outperform → Outperform | Get Alert |
| 04/24/2025 | Buy Now | -10.81% | TD Securities | $334 → $334 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2025 | Buy Now | -15.35% | JP Morgan | $311 → $317 | Maintains | Overweight | Get Alert |
| 04/16/2025 | Buy Now | — | Guggenheim | — | Reiterates | Buy → Buy | Get Alert |
| 04/10/2025 | Buy Now | -7.07% | Guggenheim | $348 → $348 | Reiterates | Buy → Buy | Get Alert |
| 04/07/2025 | Buy Now | -16.68% | RBC Capital | → $312 | Initiates | → Outperform | Get Alert |
| 02/28/2025 | Buy Now | -16.42% | Macquarie | $259 → $313 | Maintains | Outperform | Get Alert |
| 02/28/2025 | Buy Now | -7.07% | Citizens Capital Markets | $288 → $348 | Maintains | Market Outperform | Get Alert |